Mutations that Allow SIR2 Orthologs to Function in a NAD\(^+\)-Depleted Environment

**Highlights**

- Adaptive mutations in yeast Sir2 permit function with low NAD\(^+\)
- Structural rigidity of catalytic domain and overall protein stability is enhanced
- Catalytic efficiency is increased in mutant enzymes
- Mutants increase yeast replicative lifespan and deacetylation of mammalian substrates

**Authors**

Caitlin R. Ondracek, Vincent Frappier, Alison E. Ringel, Cynthia Wolberger, Leonard Guarente

**Correspondence**

leng@mit.edu

**In Brief**

Ondracek et al. report the identification of two adaptive mutations in yeast Sir2 that allow the enzyme to function in an NAD\(^+\)-depleted environment by enhancing protein stability and increasing enzyme catalysis, which increases yeast replicative lifespan and deacetylation of in vivo substrates by the Sir2 ortholog, SIRT1, in mammalian cells.
Mutations that Allow SIR2 Orthologs to Function in a NAD\textsuperscript{+}-Depleted Environment

Caitlin R. Ondracek,\textsuperscript{1} Vincent Frappier,\textsuperscript{2} Alison E. Ringel,\textsuperscript{3} Cynthia Wolberger,\textsuperscript{3} and Leonard Guarente\textsuperscript{1,4,*}

\textsuperscript{1}Glenn Center for the Science of Aging, Department of Biology, Koch Institute, MIT, Cambridge, MA 02139, USA
\textsuperscript{2}Keating Laboratory, Department of Biology, MIT, Cambridge, MA 02139, USA
\textsuperscript{3}Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
\textsuperscript{4}Lead Contact

*Correspondence: leng@mit.edu

http://dx.doi.org/10.1016/j.celrep.2017.02.031

SUMMARY

Sirtuin enzymes depend on NAD\textsuperscript{+} to catalyze protein deacetylation. Therefore, the lowering of NAD\textsuperscript{+} during aging leads to decreased sirtuin activity and may speed up aging processes in laboratory animals and humans. In this study, we used a genetic screen to identify two mutations in the catalytic domain of yeast Sir2 that allow the enzyme to function in an NAD\textsuperscript{+-} depleted environment. These mutant enzymes give rise to a significant increase of yeast replicative lifespan and increase deacetylation by the Sir2 ortholog, SIRT1, in mammalian cells. Our data suggest that these mutations increase the stability of the conserved catalytic sirtuin domain, thereby increasing the catalytic efficiency of the mutant enzymes. Our approach to identifying sirtuin mutants that permit function in NAD\textsuperscript{+-}limited environments may inform the design of small molecules that can maintain sirtuin activity in aging organisms.

INTRODUCTION

Originally discovered for its role in yeast genomic silencing, Sir2 is a nicotinamide adenine dinucleotide (NAD\textsuperscript{+})-dependent deacetylase that mediates gene silencing and aging (Imai et al., 2000). Sir2-related proteins, or sirtuins—especially the mammalian Sir2 isoform SIRT1—have been shown to modulate numerous diseases in mouse models, including metabolic disorders, neurodegeneration, cardiovascular disease, cancers, and aging (Imai and Guarente, 2014; Guarente, 2013).

Acetylation of specific lysine (Lys) residues in the amino terminus of histone proteins is recognized as a fundamental epigenetic mark that affects transcriptional regulation (Rothbart and Strahl, 2014). Histone acetylation is generally associated with transcriptional activation, as Lys residues in histone proteins neutralize negative charges along the DNA backbone. Deacetylation, therefore, results in chromatin condensation, which is associated with transcriptional repression and gene silencing. Post-translational modifications, including deacetylation, also recruit regulatory molecules to chromatin and determine the transcriptional status of genes (Allis and Jenuwein, 2000). Importantly, sirtuins also deacetylate many non-histone proteins, such as transcription factors and metabolic enzymes, and can thus exert a profound effect on cellular physiology.

Because sirtuins are dependent on NAD\textsuperscript{+}, it is possible that cellular processes modulated by sirtuins, including aging, are influenced by changes in cellular NAD\textsuperscript{+} levels. We, and others (Smith et al., 2000; Lin and Guarente, 2003), have shown that mutations in or loss of NPT1 in NAD\textsuperscript{+} biosynthetic pathways reduce NAD\textsuperscript{+} concentrations, resulting in a loss of silencing at telomeres and rDNA, as well as significantly decreasing lifespan. Importantly, NAD\textsuperscript{+} levels decline in humans and other organisms as they age (Massudi et al., 2012; Braidy et al., 2011), reducing the activity of SIRT1 and, likely, all seven mammalian sirtuins. Since loss of sirtuins has been implicated in accelerated aging (Ghosh and Zhou, 2015) and age-related diseases (Bonkowski and Sinclair, 2016), we hypothesized that, if sirtuins could function in the NAD\textsuperscript{+-} depleted environment of aging, the health benefits of these enzymes could be restored. Our approach was to use mutagenesis and a genetic screen to identify mutations that allow yeast Sir2 function to persist in a low-NAD\textsuperscript{+} setting. We identified two mutations in \textit{SIR2} that extend replicative lifespan (RLS) and increase enzymatic activity in low NAD\textsuperscript{+}. The mutations appear to cause conformational changes that improve the catalytic efficiency of Sir2, and this effect is conserved when the mutations are installed in the conserved, analogous residue in human SIRT1. Our experimentally derived data are augmented by predictive protein modeling, which supports our hypothesis that these mutations increase the rigidity of the catalytic core and stabilize the mutant enzymes. Our findings may thus identify a structural target for a class of SIRT1-activating compounds that allow activity to persist at low NAD\textsuperscript{+} levels.

RESULTS

Strains Used to Select Sir2 Mutants

The main pathways involved in NAD\textsuperscript{+} biosynthesis in yeast and other organisms are de novo synthesis of NAD\textsuperscript{+} from tryptophan (requiring Qt1) and the salvage pathway generating NAD\textsuperscript{+} from nicotinamide (requiring Pnc1) and nicotinic acid (requiring Npt1) (Bedalov et al., 2003; Lin and Guarente, 2003; Revollo et al.,...
In our initial attempts to produce yeast with low enough levels of NAD⁺ to inhibit Sir2 activity, we knocked out either OPT1 or NPT1. Only knockout of NPT1 reduced NAD⁺ levels enough to affect activity, consistent with earlier studies. This strain also contained deletions of the SIR2 and ADE2 genomic loci and had an integrated copy of ADE2 at either the rDNA or the telomeres (both locations work comparably). When transformed with a single copy of an ARS-CEN plasmid expressing SIR2, red colonies form due to silencing of ADE2, while vector control colonies not expressing Sir2 are white.

NAD⁺ levels were decreased in npt1Δ yeast ~3- to 4-fold, resulting in a significant decrease in lifespan (Figures 1A and 1B). We next assessed Sir2 activity by silencing the integrated ADE2 marker at the telomeres and rDNA. Wild-type (WT) yeast expressing Sir2 resulted in normal silencing, indicated phenotype. Differences between means are statistically significant (p < 0.0001).
expected, double-knockout yeast lacking Sir2 and NPT1 (sir2Δ npt1Δ) resulted in white colonies (Figures 1C4 and 1D4). We were able to rescue the single mutants with plasmids expressing Sir2 or NPT1 (Figures 1G5, 1G6, 1D5, and 1D6), thus resulting in red colonies. Double-knockout strains (sir2Δ npt1Δ) were not rescued with plasmids expressing either Sir2 or NPT1, resulting in white colonies (Figures 1C7, 1C8, 1D7, and 1D8). These results indicate that a threshold level of NAD⁺ is required for Sir2 to function in yeast. We used our double-knockout strain (sir2Δ npt1Δ) to select for sirtuin mutants capable of functioning in NAD⁺-depleted cells.

Identification of Sir2 Mutants that Remain Active in an NAD⁺-Deficient Environment

To test whether sirtuin activity could evolve to persist in low NAD⁺ concentrations, we screened for mutations in the Sir2 gene that potentiate function of the sir2 strain. The Sir2 gene was mutagenized along its entire conserved domain (residues 157–546) by error-prone PCR. Conditions were experimentally derived to generate approximately one to two mutations per gene and to reduce mutational bias, as monitored by DNA sequencing of individual clones after mutagenesis. When the mutagenized Sir2 plasmid was introduced into sir2Δ npt1Δ double-mutant strains with ADE2 at the rDNA or telomeres, red colonies appeared rarely; of ~30,000 colonies screened, six mutants were identified. The isolated plasmids re-transformed the sir2Δ npt1Δ mutants to produce red colonies. The six Sir2 genes were sequenced, and every mutant contained a change of Lys (K) 475 to either glutamic acid (Glu, E) or glutamine (Gln, Q). In four mutants, additional single-point mutations were present, but in two cases, the K475E and K475Q represented single-amino-acid (AA) changes, indicating that they conferred the phenotype. In Figures 1E and 1F, we show the two yeast tester strains with ADE2 at the rDNA and telomeres lacking sir2Δ npt1Δ now transformed with WT, K475E (Figure 1E), and K475Q (Figure 1F) Sir2 plasmids. WT Sir2 transformed colonies were white (Figures 1E and 1F), indicating loss of silencing and Sir2 activity, K475E and K475Q Sir2 transformed colonies were red (Figures 1E and 1F), indicating silencing of ADE2 and active Sir2 in NAD⁺-deficient cells.

Importantly, K475 lies in the Rossmann fold of the NAD⁺-binding domain of sirtuins, and the known sirtuin structures indicate that this Lys is in proximity to the NAD⁺-and substrate-binding clefts (Min et al., 2001). This residue is conserved in Sir2 orthologs among many species, including yeast, worm, mouse, and human (Figure 1G). However, comparing sequences of the yeast Sir2 and seven human sirtuin paralogs (Figure S1) revealed that, although K475 is conserved in SIRT1 (K444) and SIRT7 (K272), the other five sirtuins contain either Glu (SIRT3 E323), Gln (SIRT2 Q228; SIRT4 Q264, SIRT6 Q218), or valine (SIRT5 V253). Notably, SIRT5 is a desuccinylase and not a deacetylase (Park et al., 2013). That six of the seven mammalian sirtuins contain K, E, or Q at this site was intriguing, as these AAs possess different physicochemical properties (+, –, polar uncharged), raising the possibility that this position might play a direct role in catalysis or may alter interactions with surrounding residues to influence catalytic differences among sirtuin paralogs.

Mutant Sir2 Extends Lifespan in Both NAD⁺-Insufficient and NAD⁺-Sufficient Yeast

We next determined the RLS of yeast with the K475E or K475Q mutations integrated using pRS306 plasmids. We verified protein expression and determined that levels of WT and mutant proteins were similar in both NAD⁺-deficient (Figure 1H, top) and NAD⁺-sufficient (Figure 1I, bottom) conditions. In both NAD⁺-deficient (Figure 1H) and NAD⁺-sufficient (Figure 1I) strains, the K475 mutations significantly extended lifespan compared to WT Sir2; both Figures 1H and 1I show representative lifespan curves; one from each reporter strain used in this study but combining at least three independent experiments with 20–50 yeast cells each. Both median and maximal lifespans significantly increased (p < 0.05) with the mutant enzymes (Figure 1J; Supplemental Experimental Procedures).

Kinetic Analyses of Yeast Mutant Enzymes

To explain how these mutations confer both enhanced survival and increased silencing activity, we characterized the sirtuin mutants biochemically. We expressed ~90% pure His-tagged fusion WT and mutant Sir2 proteins (concentration verified by Coomassie staining on an SDS-PAGE protein gel) (Figure 2A). The deacetylation rate (concentration of deacetylated product produced over time; Figure S2) was determined for WT and mutant Sir2 proteins at saturating peptide (200 μM) or NAD⁺ (1 mM) concentrations against increasing concentrations of NAD⁺ (0, 0.01, 0.02, 0.05, 0.1, 0.25, 0.5, and 1.0 mM) or peptide (0, 0.05, 0.1, 0.25, 0.5, and 1.0 mM). Steady-state parameters (Michaelis-Menten constant, K_M, catalytic rate constant, k_cat) and catalytic efficiency (k_cat/K_M) were obtained using nonlinear regression of the Michaelis-Menten equation (Figures 2B and 2C); values obtained from two independent replicates are indicated by red (WT K475), teal (K475Q), and blue (K475E) circles. Experimentally derived kinetic analyses are described in Figure 2G and in the Supplemental Experimental Procedures. Overall, the turnover of the mutant enzymes was improved (increased k_cat), and K_M values for peptide (K475E) and NAD⁺ (K475Q) were lowered, which may also contribute to increased activity in vivo. While our initial hypothesis was that the K475 mutant enzymes would function by lowering K_M values for NAD⁺, our most consistent finding is an overall increase in catalytic efficiency, which may be driving the persistence of their activities in low NAD⁺ environments.

Kinetic Analyses of Human Mutant Enzymes

To determine whether these effects were limited only to yeast Sir2 or whether they extend to other species, we expressed WT SIRT1 K444 and the K444E (K444 corresponds to K475 in Sir2) mutant as His-tagged fusion proteins. We focused exclusively on the K444E mutant in SIRT1 protein, as this mutation conferred the greatest effect in Sir2 protein. We followed similar extraction and purification methods as with the yeast proteins to yield ~90% pure proteins (Figure 2D).

The steady-state parameters (K_M and k_cat) and catalytic efficiency (k_cat/K_M) were determined using the Fluor-de-Lys (FDL) SIRT1 Assay, which measures deacetylation of an acetyl-Lys substrate (FDL) comprising AAs 379–382 of human p53 (RHKK(Ac)). We determined the velocities of the WT and mutant
enzyme catalyzed reactions with increasing concentrations of FDL substrate (0, 0.01, 0.02, 0.05, 0.1, 0.25, 0.5, and 1.0 mM) and saturating concentrations of NAD$^+$ (3.0 mM), as well as with increasing concentrations of NAD$^+$ (0, 0.01, 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, and 5.0 mM) and saturating concentrations of FDL substrate (1.0 mM). Multiple independent reactions were performed. Representative sets of kinetic data for the SIRT1 K444 and SIRT1 K444E catalyzed reactions are shown in Figures 2E and 2F. Significant differences in the $V_{\text{max}}$ between WT and mutant enzymes were apparent, and the experimentally derived kinetic analyses are described (Figure 2G, bottom; Supplemental Experimental Procedures). Our results indicate that K444E SIRT1 is catalytically more active than WT (higher $k_{\text{cat}}$) and has a significantly lower $K_M$ for both substrates. Thus, it appears that enhanced catalytic efficiency is the conserved effect of the K-to-E mutation in yeast Sir2 and mammalian SIRT1. Additional kinetic analyses were performed using the SIRTainty Assay to corroborate the FDL Assay. Representative data from K444 and K444E catalyzed reactions performed with the SIRTainty Assay are shown in Figure S3. Results show increased
catalytic efficiency by the K444E enzyme, corroborating results from the FDL SIRT1 Assay.

We next examined the effect of the mutations on the actions of three compounds, the activator resveratrol and inhibitors suramin and nicotinamide. The NAD⁺ binding pocket of sirtuins is divided into three regions (Mn et al., 2001): the adenine ribose of NAD⁺ binds the A site; nicotinamide ribose binds B; and the reaction product nicotinamide binds C (Avalos et al., 2005). Suramin binds within the B and C pockets, inhibiting sirtuin reactions by blocking NAD⁺ access to the catalytic domain. Using the FDL SIRT1 Assay, we inhibited the sirtuin reaction using a range of suramin (0–1,000 μM). Results showed IC₅₀ (half maximal inhibitory concentration) values of 2.99 μM for K444 and 68.02 μM for K444E (Figure S4A), indicating that mutant K444E is much more resistant to inhibition by suramin. We next determined the effects of nicotinamide on WT and mutant SIRT1 and found IC₅₀ values of 43.05 μM for K444 and 34.27 μM for K444E (Figure S4B), indicating, at best, a slight increase of inhibition of mutant SIRT1 by nicotinamide. We also assessed the effects of resveratrol on the mammalian K444E mutant. The activation peak was shifted from 1 mM to 10 mM in the mutant. Further, the K444E mutant could not be activated by resveratrol to the degree of WT SIRT1 (Figure S4C). In a recent paper, the structure of SIRT1 in complex with resveratrol and a 7-amino-4-methylcoumarin-containing peptide showed binding of a resveratrol trimer in three different conformations, one of which directly interacts with K444 (Cao et al., 2015). We hypothesize that the K444E mutation disrupts this interaction, thus explaining the decreased binding and activation by resveratrol.

Mutant SIRT1 Enzymes Result in Decreased Acetylation of In Vivo SIRT1 Substrates

After determining the catalytic differences of both yeast and human mutant proteins in vitro, we wanted to know whether these mutations extended their effects to organisms beside yeast. To determine how mutant human SIRT1 would affect downstream targets in an in vivo cell-culture model, we evaluated differences in sirtuin activity by measuring the steady-state acetylation status of in vivo substrates. We thus performed transient transfections of HEK293T cells with SIRT1 K444, K444E, and K444Q plasmids. Transfecting 1 μg of each plasmid resulted in increased SIRT1 protein expression relative to endogenous protein expression (Figure 3A). A pan-acetyl-Lys blot of total protein revealed that cells transiently transfected with K444E or K444Q appeared to have less acetylation than K444 of multiple cellular proteins, most notably, those in the 10- to 20-kDa range, where histone proteins run on 4%–15% SDS-PAGE gels. It is known that in vivo recruitment of SIRT1 to target promoters leads to gene silencing through histone deacetylation (Vaquero et al., 2007), particularly at H4K16 and H3K9. We specifically probed for levels of H4K16ac in cells expressing SIRT1 K444E and, to a slightly lesser extent, K444Q. We observed higher levels of the mutant SIRT1 proteins in these stable lines. To determine whether this was due to differences in gene expression, we performed real-time qPCR and found that all three stable cell lines expressed similar levels of SIRT1 RNA (Figure 3D; Table S1). This finding suggested that the mutant proteins might be more stable than WT, as we address in the following text, and indicates that the increased deacetylation of H4K16 by SIRT1 mutants may be due to higher catalytic activity plus increased protein levels.

Predictive Protein Modeling Suggests Enhanced Structural Stability of Mutant Sirtuin Proteins

To gain mechanistic insight into how the mutations might result in more catalytically active enzymes and whether the stability of the protein could be altered due to the mutations, we used predictive protein modeling to examine how these single-AA changes may affect enzyme stability and function. The conserved domain sequence (residues 231–555) of Sir2 was submitted to the ENCoM web server (Frappier and Najmanovich, 2015; Supplemental Experimental Procedures), and ΔG values were calculated for WT and compared to K475 mutant enzymes, with negative ΔG values indicating increased thermodynamic structural rigidity. Strikingly, both K475E and K475Q mutations increased rigidity across the entire domain of residues 231–555 in a rank order that follows their increased kcat values (Figure 4A). Next, we used ENCoM to calculate how each K475 mutation affected the rigidity at each residue of the 231–555 domain compared to WT, using the area under the curve (AUC) of receiver operator curves (ROCs). AUCs were distributed from 0.00 to 0.5 (blue to red), where AUC = 0 corresponds to cases where the mutants had the most pronounced rigidifying effect. Compared to WT, K475E and K475Q have an average effect (red) (Figure 4B). This analysis reveals regions of increased rigidity by both mutants, compared to WT encompassing two main regions, A and B (B includes K475 itself). These regions are mapped onto the Sir2 structure, indicating the average effect of both K475E and K475Q mutations and reveal a close proximity of K475 in region B and R275 in region A (Figure 4C, region A indicated in blue and region B indicated in red). The structure, indeed, predicts that K475 and R275 exhibit a repulsive charge interaction (Figure 4D). Moreover, we hypothesize that in the K475 mutants, attractive charge-charge (K475E) or hydrogen bonding (K475Q) can now occur, which may increase the catalytic cleft stability (Figure 4D). Notably, R275 is at the acetyl-Lys binding cleft and is highly conserved in SIR2 orthologs. Since K475 and R275 are highly conserved residues, and it is well established that conserved residues are often crucial for protein function, we examined the conservation level of 150 sirtuin and sirtuin-related sequences using ConSurf (Ashkenazy et al., 2016). Residues forming the NAD⁺ and protein substrate-binding pocket were identified by contact greater than 10 Å, using a Voronoi surface algorithm between the ligand and residues within the crystal structure (McConkey et al., 2002). Blue residues indicate high conservation, and red residues indicate no conservation among species (Figure 4E).
Note that the most conserved regions in the AUC plot include regions A and B of Figure 4B.

Next, we compared the stabilization effects of the K475 mutations with all 6,156 possible AA substitutions across the 231–555 domain (324 residues multiplied by 19 AAs, minus STOP residues). We calculated a $\Delta AG$ score for each of the 6,156 mutations versus WT and ranked their $\Delta AG$ effects at each residue compared to the K475 mutations again using AUCs of the ROC (Figure 4E). Blue indicates that the K475 mutants had the most pronounced rigidifying effect compared to the 6,156 changes, and white indicates that the mutants had an average effect compared to the other 6,156 mutants. The strongest rigidifying effects of the K475 mutations compared to the other 6,156 possible changes, again, are in regions A and B. These same regions are projected onto the structure (Figure 4F) distributed from more rigid (blue) to less rigid (white) and correspond well with a projection of the most highly conserved residues onto the structure (Figure 4G). This structural analysis gives strong theoretical evidence that the K475 mutations increase the rigidity of the catalytic domain, possibly by creating charge or ionic interactions with R275, and that these changes in local dynamic properties may contribute to increased stability and increased catalytic efficiency in mutant enzymes. This might occur, for example, by reducing the time the protein is in a breathing (inactive) state.

**Mutant Human SIRT1 Shows Increased Protein Stability In Vivo and In Vitro**

The findings of ENCoM analysis predict that the mutant SIRT1 proteins display increased stability in vivo. Therefore, we assayed whether the higher levels of SIRT1 mutants were a result of increased protein stability. Various studies have measured SIRT1 half-life at between 4 and 12 hr (Gao et al., 2011; Ford et al., 2008) after using cycloheximide (CHX) to inhibit protein synthesis (Stöcklein and Piepersberg, 1980). SIRT1 null MEF lines expressing K444, K444E, and K444Q SIRT1 were treated with DMSO (solvent control) (Figure 5A) or CHX (Figure 5B), and protein lysates were collected at 0, 1, 2, 4, 8, and 12 hr post-treatment. Our results show that WT SIRT1 protein starts declining at 4 hr, with a significant loss of protein expression at 12 hr. This suggests that the increased protein stability measured in SIRT1 mutant proteins is due to their increased catalytic efficiency, possibly by reducing the time the protein is in a breathing (inactive) state.
8 and 12 hr post-treatment (Figure 5B). In contrast, both mutant SIRT1 proteins only start to decline at 8 hr; remaining >3-fold higher at 8 and 12 hr than WT protein (Figures 5C and 5D).

We also performed thermal shift assays of purified WT and mutant Sir2 proteins to determine the melting temperature (T_m) and, thus, the stability of the enzymes. We determined that the T_m increased in a rank order, with highest average T_m of 48.4 °C for K475 Sir2, 50.9 °C for K475Q, and 52.8 °C for K475E (Figures S5A and S5B). Thus, both mutant proteins demonstrate evidence of increased thermostability in vitro and are also significantly more stable in cells than WT protein.

**DISCUSSION**

In this study, we used a genetic screen to produce sirtuins capable of functioning in an NAD+-depleted environment. Sirtuins share a highly conserved catalytic domain consisting of distinct sites that bind NAD+ and protein substrates and are...
sensitive to cellular NAD+ levels. As NAD+ levels decrease with age, NAD+-dependent sirtuin activity decreases in activity. We thus genetically engineered yeast to have a 3- to 4-fold reduction in NAD+ levels, which was sufficient to abolish the red colony color due to Sir2-mediated silencing of an ADE2 gene. After mutagenesis across the conserved domain of Sir2, we screened for red transformants and identified two adaptive mutations in residue K475, which restored Sir2 activity in an NAD+-limited environment and extended yeast RLS. The in vitro kinetics analyses indicated modestly decreased KM for NAD+ by the K475Q mutant and for peptide by the K475E mutant. However, the most consistent effect observed in the mutant sirtuins was a 2- to 3-fold increase in kcat, indicating a significant increase in catalytic efficiency.

Importantly, K475 is conserved in all Sir2 orthologs. Replacing K444 (analogous to Sir2 K475) of human SIRT1 with E also increased the kcat of the human enzyme, while lower- ing the KM for both substrates. Moreover, the K444E and K444Q mutants gave rise to a higher degree of deacetylation in human and murine cells than WT. In particular, histone H4K16, a known substrate for Sir2 orthologs, was more deacetylated in cells expressing the mutants. These findings indicate that a striking functional conservation in this catalytically placed Sir2 Lys and show that the increase in catalytic efficiency conferred by this mutation extends to mammalian SIRT1.

To gain mechanistic insight into how our mutations result in more catalytically efficient enzymes, we looked into the structural changes that might occur using predictive protein modeling. The dynamic regulation of biochemical processes in the cell involves entropic effects and molecular forces between interacting groups, such as between sirtuins and their substrates (Leckband andIsraelachvili, 2001). The analysis of our mutants predicted a decreased ΔΔG, suggesting increased rigidity of the catalytic core. This analysis also suggests that the Lys mutations may exert their effects by introducing a favorable interaction with a conserved Arg (R275 in Sir2). Increased catalytic site rigidity can enhance stability and catalysis of some enzymes (Xie et al., 2014). Consistent with the predicted increase in stability, we demonstrated increased melting temperatures of mutant Sir2 enzymes in vitro and increased half-lives of mutant human sirtuins in cultured mammalian cells compared to WT protein. There are examples of improved enzymes produced using methods similar to ours, such as LovD, a natural enzyme that was transformed, using a genetic screen (Jiménez-Oses et al., 2014), into a variant 1,000-fold more efficient at synthesizing the drug simvastatin than WT LovD. This variant achieved enhanced catalysis as measured by a significant increase in kcat, not through significant changes of binding affinity (KM).

The mutations altered the conformational dynamics of the enzyme’s catalytic domain, leading to enhanced rigidity and higher thermostability. Notably, whereas our mutant sirtuins contain only one mutated residue and increased catalytic efficiency by 2- to 3-fold, mutant LovD alters 29 residues. It is plausible that sirtuin enzymes can be optimized further by including changes predicted by our modeling.

While our nicotinamide inhibition does not show significant differences between WT or mutant enzymes, we do demonstrate differential effects of mutant sirtuins compared to WT in response to resveratrol and suramin. For suramin, a large increase in the inhibitor constant Ki was observed, which may be due to the predicted higher rigidity of the catalytic core. For example, if breathing of this structure is required for suramin to bind, a lower affinity might be expected for the mutants. Of course, a more rigid catalytic domain could also inhibit the binding of certain Sir2 substrates, which require breathing of the catalytic core. In this regard, it will be of interest to examine the effects of SIRT1 K444E and K444Q mutations on many cellular substrates by a proteomics approach. For resveratrol, there appeared to be both an increase in KM and a decrease of maximal activation. Both may be due to the fact that
structural studies show that resveratrol contacts K444 (Cao et al., 2015).

In yeast, integrated copies of the mutant Sir2 genes gave rise to increased silencing compared to WT. In this case, the expression levels of all proteins were indistinguishable, so we attribute the hypermorphic phenotype of the mutants to their altered catalytic properties. In mammalian cells, however, stable lines showed slightly higher levels of mutant proteins compared to WT. Therefore, we cannot be certain whether the increase in deacetylation observed in mammalian cells expressing SIRT1 mutants is driven by higher catalytic activity, higher protein levels, or both. The higher protein levels are consistent with the mutations conferring a higher intrinsic stability. Differences in the protein turnover machinery or negative-feedback regulation (Michel et al., 2005) are possible explanations for why higher mutant protein levels were not observed in yeast.

The conserved effect of the mutations suggests a possible strategy for increasing SIRT1 activity separate from the use of conventional SIRT1-activating compounds. These compounds, including polyphenols like resveratrol and additional compounds under development at GSK (GlaxoSmithKline), work by lowering the $K_{M}$ of the enzyme for the protein substrate. We imagine that an assay similar to ours could screen for small molecules that activate yeast Sir2 in low NAD+ cells to reveal lead compounds that function like our Lys mutations and increase the catalytic efficiency of the enzyme. Such molecules may provide another translational path for activating SIRT1. Moreover, they may also activate SIRT7, which also has a Lys at the analogous position as K444 in SIRT1, and thereby exert a unique effect on cells.

In summary, we discovered that mutations in the previously uninvestigated residue, K475, to E or Q result in catalytically improved enzymes. This Lys is conserved in all Sir2 orthologs, and these mutations exert similar effects on the human enzyme. Computational and experimental methods suggest that the mutations increase the stability of two regions in the catalytic core of the enzyme. We hypothesize that, by increasing the rigidity, and thus the stability, of the catalytic domain, the K475E and K475Q enzymes breathe less and are locked into an active state, allowing faster deacetylation. Since the mutant Sir2 orthologs might function in the NAD+-depleted setting of aging, our findings may potentiate a strategy for treating diseases of aging.

**EXPERIMENTAL PROCEDURES**

**NAD+ Quantification**
NAD+ quantification was performed using the NAD/NADH Assay (Promega), following the manufacturer’s protocol and yeast-specific methods. NAD+ levels are indicated in relative light units (RLUS), relative to total protein expression.

**Yeast RLS Analysis**
Micromanipulation and RLS analysis of yeast were performed with 20–50 mother cells per experiment and carried out at least three times.

**Sir2 Deacetylation Assay**
Deacetylation of a synthetic 11-mer peptide corresponding to Lys 14 of histone H3 plus surrounding residues by WT and mutant Sir2 was measured. Reaction products were separated by HPLC on a Kinetex XB-C18 column, and product conversion was determined by comparing the ratio of deacetylated to acetylated peptide substrate.

**SIRT1 Activity: FDL Assay**
The steady-state parameters ($K_{M}$ and $k_{cat}$) and catalytic efficiency ($k_{cat}/K_{M}$) of recombinant human SIRT1 were determined using the FDL SIRT1 Fluorometric Assay. All rate measurements were obtained from three or more replicates and performed independently at least two times.

**RNA Extraction and Real-Time qPCR**
Total RNA was extracted from cells by the RNeasy Mini Kit. cDNA was synthesized using the RETROscript kit. All PCR reactions were performed in triplicate with SYBR Green in a Light Cycler 480. Relative RNA expression levels were estimated using the $\Delta\Delta CT$ method, with normalization to GAPDH and $\beta$-actin.

**Inhibition of De Novo Protein Synthesis**
MEFs were treated with 150 μg/mL CHX or DMSO. Total protein samples were harvested, and protein concentration was verified using bicinchoninic acid (BCA). Total protein was loaded on precast protein gels (Bio-Rad) and analyzed via western blotting.

**Statistical Methods**
Graphs were made and statistical analyses were performed using GraphPad Prism. Statistical analysis of yeast lifespan was determined using the log-rank (Mantel-Cox) test. Kinetic analyses were performed using the Michaelis-Menten model. Statistical analysis for qRT-PCR was determined using the $t$ test. Inhibition studies were analyzed using nonlinear exponential decay. Analyses of paired values of data were performed with paired two-tailed $t$ tests.

**SUPPLEMENTAL INFORMATION**
Supplemental Information includes Supplemental Experimental Procedures, five figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2017.02.031.

**AUTHOR CONTRIBUTIONS**
C.R.O. developed project ideas, performed experiments, and wrote the manuscript; V.F. assisted with predictive protein modeling; A.E.R. assisted with Sir2 kinetic analyses; C.W. provided the laboratory, equipment, and consultation; and L.G. developed project ideas.

**ACKNOWLEDGMENTS**
This work was supported by grants from the NIH and the Glenn Foundation for Medical Research to L.G. and by National Institute of General Medical Sciences grants to C.W. Thanks to Jonathan Renn and David Colino for critical input and to Luke Brezovec and Virginia A. Adams for lab assistance. Thanks to Su-Ju Lin and Matt Kaeberlein for sharing yeast strains and to Stephen Bell for providing plasmids. L.G. consults for Segterra, and Sebelius and is a founder of Elysium Health.

Received: November 1, 2016
Revised: December 22, 2016
Accepted: February 9, 2017
Published: March 7, 2017

**REFERENCES**
Allis, C.D., and Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487–500,
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., and Ben-Tal, N. (2016). ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 44, W344–W350.
Avalos, J.L., Bever, K.M., and Wolberger, C. (2005). Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+(−) cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17, 855–868.
Bedalov, A., Hirao, M., Posakony, J., Nelson, M., and Simon, J.A. (2003). NAD+-dependent deacetylase Hst1p controls biosynthesis and cellular NAD+ levels in Saccharomyces cerevisiae. Mol. Cell. Biol. 23, 7044–7054.

Bonkowski, M.S., and Sinclair, D.A. (2016). Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17, 679–690.

Braidy, N., Guillemin, G.J., Mansour, H., Chang-Ling, T., Pollak, A., and Grant, R. (2011). Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS ONE 6, e19194.

Cao, D., Wang, M., Qiu, X., Liu, D., Jiang, H., Yang, N., and Xu, R.M. (2015). Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev. 29, 1316–1325.

Ford, J., Ahmed, S., Allison, S., Jiang, M., and Milner, J. (2008). JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 7, 3091–3097.

Frappier, V., and Najmanovich, R. (2015). Vibrational entropy differences between mesophile and thermophile proteins and their use in protein engineering. Protein Sci. 24, 474–483.

Gao, Z., Zhang, J., Kheterpal, I., Kennedy, N., Davis, R.J., and Ye, J. (2011). Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J. Biol. Chem. 286, 22227–22234.

Ghosh, S., and Zhou, Z. (2015). SIRTain regulators of premature senescence and accelerated aging. Protein Cell 6, 322–333.

Guarente, L. (2013). Calorie restriction and sirtuins revisited. Genes Dev. 27, 2072–2085.

Imai, S., and Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24, 464–471.

Imai, S., Armstrong, C.M., Kaebeltein, M., and Guarente, L. (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800.

Jiménez-Osés, G., Osuna, S., Gao, X., Sawaya, M.R., Gilson, L., Collier, S.J., Huisman, G.W., Yeates, T.O., Tang, Y., and Houk, K.N. (2014). The role of distant mutations and allosteric regulation on LovD active site dynamics. Nat. Chem. Biol. 10, 431–436.

Leckband, D., and Israelachvili, J. (2001). Intermolecular forces in biology. Q. Rev. Biophys. 34, 105–267.

Lin, S.-J., and Guarente, L. (2003). Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr. Opin. Cell Biol. 15, 241–246.

Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., and Guillemin, G.J. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE 7, e42357.

McConkey, B.J., Sobolev, V., and Edelman, M. (2002). Quantification of protein surfaces, volumes and atom-atom contacts using a constrained Voronoi procedure. Bioinformatics 18, 1365–1373.

Michel, A.H., Kommann, B., Dubrana, K., and Shore, D. (2005). Spontaneous rDNA copy number variation modulates Sir2 levels and epigenetic gene silencing. Genes Dev. 19, 1199–1210.

Min, J., Landry, J., Sternglanz, R., and Xu, R.M. (2001). Crystal structure of a Sir2 homolog-NAD complex. Cell 105, 269–279.

Park, J., Chen, Y., Tishkoff, D.X., Peng, C., Tan, M., Dai, L., Xie, Z., Zhang, Y., Zwaans, B.M., Skinner, M.E., et al. (2013). SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol. Cell 50, 919–930.

Revollo, J.R., Grimm, A.A., and Imai, S. (2004). The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754–50763.

Smith, J.S., Brachmann, C.B., Celic, I., Kenna, M.A., Muhammad, S., Starai, V.J., Avalos, J.L., Escalante-Semerena, J.C., Grubmeyer, C., Wolberger, C., and Boeke, J.D. (2000). A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. USA 97, 6658–6663.

Stöcklein, W., and Piepersberg, W. (1980). Binding of cycloheximide to ribosomes from wild-type and mutant strains of Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 18, 863–867.

Vaquero, A., Sternglanz, R., and Reingberg, D. (2007). NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 26, 5505–5520.

Xie, Y., An, J., Yang, G., Wu, G., Zhang, Y., Cui, L., and Feng, Y. (2014). Enhanced enzyme kinetic stability by increasing rigidity within the active site. J. Biol. Chem. 289, 7994–8006.